The MYC dualism in growth and death

Mutation Research - Reviews in Mutation Research

Volumn 437, Issue 3, 1999, Pages 205-217

  Fuhrmann, Gerhard ^a   Rosenberger, Georg ^a   Grusch, Michael ^a   Klein, Nikolas ^a   Hofmann, Johannes ^b   Krupitza, Georg ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Apoptosis; c Myc; Target genes

Indexed keywords

CYTOSTATIC AGENT; ESTROGEN RECEPTOR; FAS LIGAND; FERRITIN; ORNITHINE DECARBOXYLASE; POLYAMINE OXIDASE; PUTRESCINE; RETINOIC ACID; SPERMIDINE; SPERMINE; TAMOXIFEN; TELOMERASE; TRANSCRIPTION FACTOR;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; GENE CONTROL; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REPRESSOR GENE; REVIEW;

EID: 0032711964     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00084-8     Document Type: Article

References (166)

1. Hayward W.S., Neel B.G., Astrin S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature. 290:1981;475-480.
2. Bishop J.M. Cellular oncogenes and retroviruses. Annu. Rev. Biochem. 52:1983;301-354.
3. Bouchard C., Staller P., Eilers M. Control of cell proliferation by Myc. Trends Cell Biol. 8:1998;202-206.
4. Klein G. The role of gene dosage and genetic transpositions in carcinogenesis. Nature. 294:1981;313-318.
5. Cochran B.H., Reffel A., Stiles C. Molecular cloning of gene sequences regulated by platelet-derived growth factor. Cell. 33:1983;939-947.
6. Amati B., Konstantinos A., Vlach J. Myc and the cell cycle. Front. Biochem Sci. 3:1998;d250-d268.
7. Boldogh I., AbuBakar S., Albrecht T. Activation of proto-oncogenes: an immediate early event in human cytomegalovirus infection. Science. 247:1990;561-564.
8. Curran T., Bravo R., Müller R. Transient induction of c-fos and c-myc in an immediate consequence of growth factor stimulation. Cancer Surv. 4:1985;655-681.
9. Lemaitre J.M., Buckle R.S., Mechali M. c-Myc in the control of cell proliferation and embryonic development. Adv. Cancer Res. 70:1996;96-144.
10. Henriksson M., Lüscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv. Cancer Res. 68:1996;109-182.
11. Greenberg M.E., Hermanowski A.L., Ziff E.B. Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription. Mol. Cell. Biol. 6:1986;1051-1057.
12. Marcu K.B., Bossone S.A., Patel A.J. myc function and regulation. Annu. Rev. Biochem. 61:1992;809-860.
13. Grandori C., Eisenman R.N. Myc target genes. TIBS. 22:1997;177-181.
14. Ruley H.E. Transforming collaborations between ras and nuclear oncogenes. Cancer Cells. 2:1990;258-268.
15. Wu K., Grandori C., Amacker M., Simon-Vermont N., Polack A., Lingner J., Dalla-Favera R. Direct activation of TERT transcription by c-Myc. Nat. Gen. 21:1999;220-224.
16. Land H., Parada L., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:1983;596-602.
17. Stone J., de-Lange T., Ramsay G., Jakobovits E., Bishop J.M., Varmus H., Lee W. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 7:1987;1697-1709.
18. Land H., Chen A.C., Morgenstern J.P., Parada L.F., Weinberg R.A. Behavior of myc and ras Oncogenes in transformation of rat embryo fibroblasts. Mol. Cell. Biol. 6:1986;1917-1925.
19. Land H., Parada L.F., Weinberg R.A. Cellular Oncogenes and multistep carcinogenesis. Science. 222:1983;771-778.
20. Mukherjee B., Morgenbesser S., DePinho R.A. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants. Genes Dev. 6:1992;1480-1492.
21. Katzav S., Packham G., Sutherland M., Aroca P., Santos E., Cleveland J.L. Vav and Ras induce fibroblast transformation by overlapping signaling pathways which require c-Myc function. Oncogene. 11:1995;1079-1088.
22. Yin X.Y., Grove L., Datta N.S., Long M.W., Prochownik E.V. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene. 18:1999;1177-1184.
23. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene. 4:1989;715-724.
24. Thompson T.C., Southgate J., Kitchener G., Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell. 56:1989;917-930.
25. Haupt Y., Harris A.W., Adams J.M. Retroviral infection accelerates T lymphomagenesis in E mu-N-ras transgenic mice by activating c-myc or N-myc. Oncogene. 7:1992;981-986.
26. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 49:1987;465-475.
27. Allen J.D., Verhoeven E., Domen J., van der Valk M., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 15:1997;1133-1141.
28. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., Berns A. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 56:1989;673-682.
29. Verbeek S., van Lohuizen M., van der Valk M., Domen J., Kraal G., Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol. Cell. Biol. 11:1991;1176-1179.
30. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1997;1039-1048.
31. Born T.L., Frost J., Schonthal A., Prendergast G., Feramisco J.R. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol. Cell. Biol. 14:1994;5710-5718.
32. Harrington E.A., Bennett M.R., Fanidi A., Evan G.I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
33. Seth A., Gupta S., Davis R.J. Cell cycle regulation of the c-Myc transcriptional activation domain. Mol. Cell. Biol. 13:1993;4125-4136.
34. Shibuya H., Yoneyama M., Ninomiya-Tsuji J., Matsumoto K., Taniguchi T. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc. Cell. 70:1992;57-67.
35. Morales C., Holt S., Quellette M., Kaur K., Yan Y., Wilson K., White M., Wright W., Shay J. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat. Gen. 21:1999;115-118.
36. Garte S. The c-myc Oncogene in tumor progression. Crit. Rev. Oncog. 4:1993;435-449.
37. Schwab M., Ellison J., Busch M., Rosenau W., Varmus H., Bishop J.M. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc. Natl. Acad. Sci. USA. 81:1984;4940-4944.
38. Brodeur G.M., Seeger R.C., Schwab M., Varmus H., Bishop J.M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 224:1984;1121-1124.
39. Yokota J., Tsunetsugu-Yokota Y., Battifora H., Le-Fevre C., Cline M.J. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science. 231:1986;261-265.
40. Little C.D., Nau M.M., Carney D.N., Gazdar A.F., Minna J.D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 306:1983;194-196.
41. Korc M., Meltzer P., Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA. 83:1986;470-473.
42. Kozbor D., Croce C.M. Amplification of the c-myc oncogene in one of five human breast carcinoma cell lines. Cancer Res. 44:1984;438-441.
43. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M.H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA. 83:1986;4834-4838.
44. Alitalo K., Schwab M., Lin C.C., Varmus H.E., Bishop J.M. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc. Natl. Acad. Sci. USA. 80:1983;1707-1711.
45. Sumegi J., Hedberg T., Bjorkholm M., Godal T., Mellstedt H., Nilsson M.G., Perlman C., Klein G. Amplification of the c-myc oncogene in human plasma-cell leukemia. Int. J. Cancer. 36:1985;367-371.
46. Collins S., Groudine M. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature. 298:1982;679-681.
47. Dalla-Favera R., Wong-Staal F., Gallo R.C. Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature. 299:1982;61-63.
48. McCarthy D.M., Rassool F.V., Goldman J.M., Graham S.V., Birnie G.D. Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia. Lancet. 2:1984;1362-1365.
49. Sakamuro D., Elliott K., Wechsler-Reya R., Prendergast G.C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat. Gen. 14:1996;69-77.
50. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55:1990;133-270.
51. Siebert R., Matthiesen P., Harder S., Zhang Y., Borowski A., Zuhlke-Jenisch R., Metzke S., Joos S., Weber-Matthiesen K., Grote W., Schlegelberger B. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood. 91:1998;984-990.
52. Erikson J., Finger L., Sun L., Ar-Rushdi A., Nishikura K., Minowada J., Finan J., Emanuel B.S., Nowell P., Croce C.M. Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias. Science. 232:1986;884-886.
53. Finver S.N., Nishikura K., Finger L., Haluska F., Finan J., Nowell P.C., Croce C.M. Sequence analysis of the MYC oncogene involved in the t(8;14)(q24;q11) chromosome translocation in a human leukemia T-cell line indicates that putative regulatory regions are not altered. Proc. Natl. Acad. Sci. USA. 85:1988;3052-3056.
54. Kagan J., Finger L., Letofsky J., Finan J., Nowell P., Croce C.M. Clustering of breakpoints on chromosome 10 in acute T-cell leukemias with the t(10;14) chromosome translocation. Proc. Natl. Acad. Sci. USA. 86:1989;4161-4165.
55. Peschle C., Mavilio F., Sposi N., Giampaolo A., Care A., Bottero L., Bruno M., Mastroberardino G., Gastaldi R., Testa M. Translocation and rearrangement of c-myc into immunoglobulin alpha heavy chain locus in primary cells from acute lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 81:1984;5514-5518.
56. Care A., Cianetti L., Giampaolo A., Sposi N., Zappavigna V., Mavilio F., Alimena G., Amadori S., Mandelli F., Peschle C. Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. EMBO J. 5:1986;905-911.
57. Payne G.S., Bishop J.M., Varmus H.E. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature. 295:1982;209-214.
58. Westaway D., Payne G., Varmus H.E. Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors. Proc. Natl. Acad. Sci. USA. 81:1984;843-847.
59. Linial M., Groudine M. Transcription of three c-myc exons is enhanced in chicken bursal lymphoma cell lines. Proc. Natl. Acad. Sci. USA. 82:1985;53-57.
60. Penn L.J., Brooks M., Laufer E., Land H. Negative autoregulation of c-myc transcription. EMBO J. 9:1990;1113-1121.
61. Judware R., Culp L.A. Concomitant down-regulation of expression of integrin subunits by N-myc in human neuroblastoma cells: differential regulation of alpha2, alpha3 and beta1. Oncogene. 14:1997;1341-1350.
62. Inghirami G., Grignani F., Sternas L., Lombardi L., Knowles D., Dalla-Favera R. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. Science. 250:1990;682-686.
63. Versteeg R., Noordermeer I., Kruse-Wolters M., Ruiter D., Schrier P. c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 7:1988;1023-1029.
64. Tikhonenko A.T., Black D., Linial M. Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J. Biol. Chem. 271:1996;30741-30747.
65. Roy A.L., Carruthers C., Gutjahr T., Roeder R.G. Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature. 365:1993;359-361.
66. Peukert K., Staller P., Schneider A., Carmichael G., Hanel F., Eilers M. An alternative pathway for gene regulation by myc. EMBO J. 16:1997;5672-5686.
67. Wu K., Polack A., Dalla-Favera R. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-Myc. Science. 283:1999;676-679.
68. Thompson E.B. The many roles of c-Myc in apoptosis. Annu. Rev. Physiol. 60:1998;575-600.
69. Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922.
70. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-Myc protein. Cell. 69:1992;119-128.
71. Harris A.W., Pinkert C., Crawford M., Langdon W., Brinster R., Adams J.M. The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167:1988;353-371.
72. Jacobsen K.A., Prasad V.S., Sidman C., Osmond D.G. Apoptosis and macrophage-mediated deletion of precursor B cells in the bone marrow of Eμ-myc transgenic mice. Blood. 84:1994;2784-2794.
73. Prasad V.S., LaFond R., Zhou M., Jacobsen K., Osmond D.G., Sidman C.L. Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of Eμ-myc transgenic mice by deregulated c-myc transgene. Mol. Carcinogenesis. 18:1997;66-77.
74. Amundadottir L.T., Nass S., Berchem G.J., Johnson M.D., Dickson R.B. Cooperation of TGF and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene. 13:1996;757-765.
75. Hundley J.E., Koester S.K., Troyer D.A., Hilsenbeck S.G., Barrington R., Windle J. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. Cancer Res. 57:1997;600-603.
76. Morgenbesser S.D., DePinho R.A. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Semin. Cancer Biol. 5:1994;21-36.
77. Davis A.C., Wims M., Spotts G., Hann S., Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7:1993;671-682.
78. Hueber A.O., Zornig M., Lyon D., Suda T., Nagata S., Evan G.I. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 278:1997;1305-1309.
79. Havlicek L., Hanus J., Vesely J., Leclerc S., Meijer L., Shaw G., Strnad M. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J. Med. Chem. 40:1997;408-412.
80. Packham G., Cleveland J. c-Myc and apoptosis. Biochim. Biophys. Acta. 1242:1995;11-28.
81. King K.L., Cidlowski J.A. Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 60:1998;601-617.
82. Kaptein J.S., Lin C.K.E., Wang C.L., Nguyen T.T., Kalunta C.I., Park E., Chen F.S., Lad P.M. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis. J. Biol. Chem. 271:1996;18875-18884.
83. McCormack J.E., Pepe V., Kent R.B., Dean M., Marshak-Rothstein A., Sonenshein G.E. Specific regulation of c-myc oncogene expression in a murine B-cell lymphoma. Proc. Natl. Acad. Sci. USA. 81:1984;5546-5550.
84. Fischer G., Kent S.C., Joseph L., Green D.R., Scott D.W. Lymphoma models for B cell activation and tolerance. X. Anti-μ-mediated growth arrest and apoptosis of murine B cell lymphomas are prevented by the stabilization of myc. J. Exp. Med. 179:1994;221-228.
85. Hengstschlager M., Holzl G., Hengstschlager-Ottnad E. Different regulation of c-Myc- and E2F-1-induced apoptosis during the ongoing cell cycle. Oncogene. 18:1999;843-848.
86. O'Connor R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G.I., Baserga R., Blattler W.A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol. Cell. Biol. 17:1997;427-435.
87. Janicke R., Lee F., Porter A. Nuclear c-myc plays an important role in the cytotoxicity of tumor necrosis factor alpha in tumor cells. Mol. Cell. Biol. 14:1994;5661-5670.
88. Klefstrom J., Vastrik I., Saksela E., Valle J., Eilers M., Alitalo K. C-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 13:1994;5442-5450.
89. Simonitsch I., Krupitza G. Autocrine self elimination of cultured ovarian cancer cells by TNFα Br. J. Cancer. 78:1998;862-870.
90. Sumitani K., Kamijo R., Nagumo M. Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression. Anticancer Res. 17:1997;865-871.
91. Fornari F.A. Jr., Jarvis W.D., Grant S., Orr M., Randolph J., White F.K., Mumaw V.R., Lovings E.T., Freeman R., Gewirtz D.A. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ. 5:1994;723-733.
92. Ohta H., Sweeney E.A., Masamune A., Yatomi Y., Hakomori S., Igarashi Y. Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res. 55:1995;691-697.
93. Davidoff A.N., Mendelow B.V. c-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis. Anticancer Res. 13:1993;1167-1170.
94. Kimura S., Maekawa T., Hirakawa K., Murakami A., Abe T. Alteration of c-myc expression by antisense oligodeoxynucleotides enhances the induction of apoptosis in HL-60 cells. Cancer Res. 55:1995;1379-1384.
95. Shimamoto T., Nakamura S., Bollekens J., Ruddle F., Takeshita K K. Inhibition of DLX-7 homeobox gene causes decreased expression of GATA-1 and c-myc genes and apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;3245-3249.
96. Eilers M., Schirm S., Bishop J.M. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J. 10:1991;133-141.
97. Gaubatz S., Meichle A., Eilers M. An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc. Mol. Cell. Biol. 14:1994;3853-3862.
98. Bello-Fernandez C., Packham G., Cleveland J.L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA. 90:1993;7804-7808.
99. Wagner A.J., Meyers C., Laimins L.A., Hay N. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ. 4:1993;879-883.
100. Packham G., Cleveland J.L. The role of ornithine decarboxylase in c-Myc-induced apoptosis. Curr. Top. Microbiol. Immunol. 194:1995;283-290.
101. Amati B., Dalton S., Brooks M.W., Littlewood T.D., Evan G.I., Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 359:1992;423-426.
102. Kretzner L., Blackwood E.M., Eisenman R.N. Myc and Max proteins possess distinct transcriptional activities. Nature. 359:1992;426-429.
103. Amati B., Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr. Opin. Genet. Dev. 4:1994;102-108.
104. Amati B., Brooks M.W., Levy N., Littlewood T.D., Evan G.I., Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 72:1993;233-245.
105. Amati B., Littlewood T.D., Evan G.I., Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12:1993;5083-5087.
106. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 25:1991;1211-1217.
107. Prendergast G.C., Lawe D., Ziff E. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell. 65:1991;395-407.
108. Blackwood E.M., Kretzner L., Eisenman R.N. Myc and Max function as a nucleoprotein complex. Curr. Opin. Genet. Dev. 2:1992;227-235.
109. Prendergast G.C., Ziff E.B. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science. 251:1991;186-189.
110. Blackwell T.K., Huang L., Ma A., Kretzner L., Alt F.W., Eisenman R., Weintraub H. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol. Cell. Biol. 13:1993;5216-5224.
111. Grandori C., Mac J., Siebelt F., Ayer D., Eisenman R. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J. 15:1996;4344-4357.
112. Solomon D., Amati B., Land H. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res. 21:1993;5372-5376.
113. Desbarats L., Gaubatz S., Eilers M. Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev. 10:1996;447-460.
114. Fisher F., Crouch D.H., Jayaraman P., Clark W., Gillespie D., Goding C. Transcription activation by Myc and Max: flanking sequences target activation to a subset of CACGTG motifs in vivo. EMBO J. 12:1993;5075-5082.
115. Hopewell R., Ziff E. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol. Cell. Biol. 15:1995;3470-3478.
116. Butt T., Karathanasis S. Transcription factors as drug targets: opportunities for therapeutic selectivity. Gene Expression. 4:1995;319-336.
117. Eilers M., Picard D., Yamamoto K.R., Bishop J.M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature. 340:1989;66-68.
118. Littlewood T., Hancock D., Danielian P., Parker M., Evan G.A. Modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of hetreologous proteins. Nucleic Acids Res. 23:1995;1686-1690.
119. Krupitza G., Hulla W., Harant H., Dittrich E., Kallay E., Huber H., Dittrich C. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int. J. Cancer. 61:1995;649-657.
120. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 382:1996;511-517.
121. MacLachlan T.K., Sang N., Giordano A. Cyclins, cyclin dependent kinases and cdk inhibitors: implications in the cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expression. 5:1995;127-156.
122. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D. CDC25 phosphatases as potential human Oncogenes. Science. 269:1995;1575-1577.
123. Vlach J., Hennecke S., Alevizopoulos K., Conti D., Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15:1996;6595-6604.
124. Steiner P., Philipp A., Lukas J., Godden-Kent D., Pagano M., Mittnacht S., Bartek J., Eilers M. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 14:1995;4814-4826.
125. Tabor C., Tabor H. Polyamines, Annu. Rev. Biochem. 53:1984;749-790.
126. Pegg P.A. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem. J. 234:1986;249-262.
127. Schuber F. Influence of polyamines on membrane functions. Biochem. J. 260:1989;1-10.
128. Heby O., Persson L. Molecular genetics of polyamine synthesis in eukaryotic cells trends. Biochem. Sci. 15:1990;153-158.
129. Packham G., Cleveland J. Ornithine decarboxylase Is a Mediator of c-Myc induced apoptosis. Mol. Cell. Biol. 14:1994;5741-5747.
130. Packham G., Porter C.W., Cleveland J.L. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene. 13:1996;461-469.
131. Desiderio M., Grassilli E., Bellesina E., Salomoni P., Franceschi C. Involvement of Ornithine decarboxylase and polyamines in glucocorticoid induced apoptosis of rat thymocytes. Cell Death Differ. 6:1995;505-513.
132. Auvinen M., Paasinen A., Anderson L.C., Hölttä E. Ornithine decarboxylase activity is critical for cell transformation. Nature. 360:1992;355-358.
133. Moshier J.A., Dosescu J., Skunca M., Luk G.D. Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res. 53:1993;2618-2622.
134. Shantz L.M., Pegg A.E. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 54:1994;2313-2316.
135. Kangas A., Nicholson D.W., Hottla E. Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis. Oncogene. 16:1998;387-398.
136. Zhan Y., Cleveland J.L., Stevens J.L. A role for c-myc in chemically induced renal-cell death. Mol. Cell. Biol. 17:1997;6755-6764.
137. Tome M., Fiser S., Payne C., Gerner E. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem. J. 328:1997;847-854.
138. Xie X., Tome M.E. Gerner EW Loss of intracellular putrescine pool-size regulation induces apoptosis. Exp. Cell Res. 230:1997;386-392.
139. Tobias K.E., Kahana C. Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. Cell Growth Differ. 6:1995;1279-1285.
140. Sieler N., Bolkenius F., Knodgen B. The influence of catabolic reactions on polyamine secretion. Biochem. J. 225:1985;219-226.
141. Brune B., Hartzell P., Nicotera P., Orrenius S. Spermine prevents endonuclease activation and apoptosis in thymocytes. Exp. Cell Res. 195:1991;323-329.
142. Lin C.K., Zou H.Y., Kaptein J.S., Yen C.F., Kalunta C.I., Nguyen T.T., Park E., Lad P.M. Anti-IgM-induced growth inhibition and apoptosis are independent of ornithine decarboxylase in Ramos cells. Exp. Cell Res. 237:1997;231-241.
143. Grassilli E., Desiderio M.A., Bellesia E., Salomoni P., Benatti F., Franceschi C. Is polyamine decrease a common feature of apoptosis? Evidence from gamma rays- and heat shock-induced cell death. Biochem. Biophys. Res. Commun. 216:1995;708-714.
144. Krupitza G., Grusch M., Braun K., Fuhrmann G., Steinbrugger R., Hulla W., Simonitsch I., Chott A., Hengstschläger M. TNFα-mediated cell death is independent of Cdc25A. Cell Death Differ. 5:1998;758-764.
145. Perez-Roger I., Solomon D., Sewing A., Land H. Myc activation of cyclinE/Cdk2 kinase involves induction of cyclinE gene transcription and inhibition of p27 binding to newly formed complexes. Oncogene. 14:1997;2373-2381.
146. Pusch O., Bernaschek G., Eilers M., Hengstschläger M. Activation of c-Myc uncouples DNA-replication from activation of G1-cyclin dependent kinases. Oncogene. 15:1997;649-656.
147. Szekeres T., Fritzer-Szekeres M., Elford H.L. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit. Rev. Clin. Lab. Sci. 34:1997;503-528.
148. Marhin W.W., Hei Y., Chen S., Jiang Z., Gallie B., Phillips R.A., Penn L.Z. Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation. Oncogene. 12:1996;43-52.
149. Solomon D.L., Philipp A., Land H., Eilers M. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Oncogene. 11:1995;1893-1897.
150. Leardi A.M., Caraglia M., Selleri C., Pepe S., Pizzi C., Notaro R., Fabbrocini A., De-Lorenzo S., Musico M., Abbruzzese A., Bianco A., Tagliaferri P. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br. J. Haematol. 102:1998;746-752.
151. Ayer D.E., Kretzner L., Eisenman R.N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell. 72:1993;211-222.
152. Zervos A.S., Gyuris J., Brent R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell. 72:1993;223-232.
153. Hurlin P.J., Queva C., Koskinen P.J., Steingrimsson E., Ayer D.E., Copeland N.G., Jenkins N.A., Eisenman R.N. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 14:1995;5646-5659.
154. Roussel M., Ashmun R., Sherr C., Eisenman R.N., Ayer D. Inhibition of cell proliferation by the Mad1 transcriptional repressor. Mol. Cell. Biol. 16:1996;2796-2801.
155. Ayer D.E., Eisenma R.N. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev. 7:1993;2110-2119.
156. Chin L., Schreiber A.N., Pellicer I., Chen K., Lee H.W., Dudast M., Cordon C.C., DePinho R.A. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc. Natl. Acad. Sci. USA. 92:1995;8488-8492.
157. Laherty C.D., Yang W., Sun J., Davie J., Seto E., Eisenman R.N. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 89:1997;349-356.
158. Sommer A., Hilfenhaus S., Menkel A., Kremmer E., Seiser C., Loidl P., Lüscher B. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. Curr. Biol. 7:1997;357-365.
159. Hurlin P., Quéva C., Eisenman R. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev. 11:1997;44-58.
160. Meroni G., Reymond A., Alcalay M., Borsani G., Tanigami A., Tonlorenzi R., Nigro C.L., Messali S., Zollo M., Ledbetter D.H., Brent R., Ballabio A., Carrozzo R. Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor. EMBO J. 16:1997;2892-2906.
161. Shrivastava A., Yu J., Artandi S., Calame K. YY1 and c-Myc associate in vivo in a manner that depends on c-Myc levels. Proc. Natl. Acad. Sci. USA. 93:1996;10638-10641.
162. Alexandrow M.G., Kawabata M., Aakre M., Moses H.L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor ß1. Proc. Natl. Acad. Sci. USA. 92:1995;3239-3243.
163. Hermeking H., Funk J.O., Reichert M., Ellwart J.W., Eick D. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 11:1995;1409-1415.
164. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
165. Oswald F., Lovec H., Moroy T., Lipp M. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene. 9:1994;2029-2036.
166. DeGregori J., Kowalik T., Nevins J. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15:1995;4215-4224.